TITLE

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes

AUTHOR(S)
BOLLI, GEREMIA B.; LUCIDI, PAOLA; PORCELLATI, FRANCESCA; FANELLI, CARMINE G.
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS220
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the role of timely basal insulin replacement after metformin failure to sustain long-term blood glucose control in type 2 diabetes. Early and aggressive blood glucose-lowering intervention are used in addressing macrovascular complications. A discussion on the outcomes of clinical studies which compared basal insulin and glucagon-like peptide (GLP)-1 agonists in type 2 diabetes is presented. Upon failure of metformin and lifestyle intervention, insulin will be initiated and the add-on treatment of sulfonylurea (SU) will be bypassed.
ACCESSION #
61968015

 

Related Articles

  • Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Giorgino, Francesco; Benroubi, Marian; Jui-Hung Sun; Zimmermann, Alan G.; Pechtner, Valeria; Sun, Jui-Hung // Diabetes Care;Dec2015, Vol. 38 Issue 12, p2241 

    Objective: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary...

  • On the Horizon. Karl, Elka // Diabetes Health;Oct2004, Vol. 13 Issue 10, p74 

    Presents a study on the effect of the combination of glucagon-like peptide (GLP-1) and Actos or pioglitazone on blood glucose levels. Treatments used in the study; Effect of GLP-1 monotherapy on insulin levels; Conclusion of the study.

  • Glucagon-like peptide-1 receptor agonists for intensifying diabetes treatment. Bush, Michael A. // Journal of Family Practice;Sep2011 Supplement 1, Vol. 60, pS11 

    The article focuses on the efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists in diabetic treatment. It mentions that GLP-1R agonist with the combination of lifestyle management can reduce the glycated hemoglobin (A1C) level by 0.5% to 1.5%. It states the effectiveness of GLP-1R...

  • Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness. Juhl, C. B.; Schmitz, O.; Pincus, S.; Holst, J. J.; Veldhuis, J.; Pørksen, N. // Diabetologia;May2000, Vol. 43 Issue 5, p583 

    Aims/hypothesis. The enteric incretin hormone, glucagon-like peptide-1 (GLP-1), is a potent insulin secretagogue in healthy humans and patients with Type II (non-insulin-dependent) diabetes mellitus. In this study we assessed the impact of short-term GLP-1 infusion on pulsatile insulin secretion...

  • Oxyntomodulin Increases Insulin Secretion but Does Not Affect Insulin Sensitivity in High-Fat-Fed C57B1/6 Mice. Parlevliet, Edwin T.; Heijboer, Annemieke C.; Schröder-Van Der Elst, Janny P.; Havekes, Louis M.; Romijn, Johannes A.; Pijl, Hanno; Corssmit, Eleonora P. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA373 

    Gut-derived peptides like ghrelin and glucagon-like peptide (GLP-1) affect glucose metabolism in many ways, e.g. by altering insulin sensitivity or secretion. The proglucagon-derived peptide oxyntomodulin (OXM) is cosecreted with GLP-1 and inhibits feeding in rodents and man. We evaluated the...

  • Insulin Secretion, Insulin Resistance and Incretin Hormones in Individuals with Impaired Fasting Glycemia and Impaired Glucose Tolerance. Faerch, Kristine; Vaag, Allan; Holst, Jens J.; Borch-Johnsen, Knut // Diabetes;Jun2007 Supplement 1, Vol. 56, pA383 

    The article discusses a study on insulin resistance and the secretion of insulin and incretin hormones in individuals with impaired fasting glycemia (IFG) and impaired glucose tolerance (IGT). It was found that IGT is characterized by insulin resistance and lack of compensatory increase in...

  • Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target? D'Alessio, David A. // Diabetes;Jul2010, Vol. 59 Issue 7, p1572 

    The author discusses a study which quantified the contributions of insulin and glucagon to mediate glucagon-like peptide 1 (GLP-1)-induced changes in blood glucose, published within the issue. The study included middle-aged men with well-controlled type 2 diabetes. Study researchers concluded...

  • Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1. Mingming Gao; Hong Tian; Chen Ma; Xiangdong Gao; Wei Guo; Wenbing Yao // Applied Biochemistry & Biotechnology;Sep2010, Vol. 162 Issue 1, p155 

    Glucagon-like peptide-1 (GLP-1) is attracting increasing interest on account of its prominent benefits in type 2 diabetes. However, its clinical application is limited because of short biological half-life. This study was designed to produce a C-terminal site-specific PEGylated analog of...

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics